Use of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 1, 2015, Pages 147-154

  Garcia Martinez, Irma ^a   Francés, Rubén ^a,b   Zapater, Pedro ^a,b   Giménez, Paula ^a   Gómez Hurtado, Isabel ^a   Moratalla, Alba ^a   Lozano Ruiz, Beatriz ^a   Bellot, Pablo ^a   González Navajas, José M ^a   Such, José ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Bacterial DNA; Cirrhosis; Norfloxacin; Oxidative burst; Proton pump inhibitors

Indexed keywords

BACTERIAL DNA; NITRIC OXIDE; NORFLOXACIN; PROTON PUMP INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; ASCITES FLUID; BACTERIAL INFECTION; BACTERIAL TRANSLOCATION; BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; FLOW CYTOMETRY; FLOW RATE; GRANULOCYTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY BURST; AGED; BACTERIAL INFECTIONS; BLOOD; CHEMICAL PHENOMENA; COMPLICATION; DRUG EFFECTS; DRUG INTERACTION; IMMUNOLOGY; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED;

AGED; BACTERIAL INFECTIONS; BACTERIAL TRANSLOCATION; DEPRESSION, CHEMICAL; DRUG INTERACTIONS; FEMALE; GRANULOCYTES; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MONOCYTES; NORFLOXACIN; PHAGOCYTOSIS; PROTON PUMP INHIBITORS; RESPIRATORY BURST;

EID: 84919645010     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12667     Document Type: Article

References (36)

1. Such J, Runyon BA. Spontaneous bacterial peritonitis. Clin. Infect. Dis. 1998; 27: 669-674; quiz 75-6.
2. Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect. Immun. 1979; 23: 403-411.
3. Rimola A, Soto R, Bory F, Arroyo V, Piera C, Rodes J. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 1984; 4: 53-58.
4. Guarner C, Runyon BA. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, and management. Gastroenterologist 1995; 3: 311-328.
5. Byl B, Roucloux I, Crusiaux A, Dupont E, Deviere J. Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients. Gastroenterology 1993; 104: 1492-1497.
6. Frances R, Zapater P, Gonzalez-Navajas JM etal. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008; 47: 978-985.
7. Zapater P, Frances R, Gonzalez-Navajas JM etal. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology 2008; 48: 1924-1931.
8. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J. Clin. Pharm. Ther. 2000; 25: 333-340.
9. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am. J. Gastroenterol. 2000; 95: 3118-3122.
10. Chavez-Tapia NC, Tellez-Avila FI, Garcia-Leiva J, Valdovinos MA. Use and overuse of proton pump inhibitors in cirrhotic patients. Med. Sci. Monit. 2008; 14: CR468-472.
11. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009; 301: 2120-2128.
12. Goel GA, Deshpande A, Lopez R, Hall GS, van Duin D, Carey WD. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic Acid suppression. Clin. Gastroenterol. Hepatol. 2012; 10: 422-427.
13. Bajaj JS, Zadvornova Y, Heuman DM etal. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am. J. Gastroenterol. 2009; 104: 1130-1134.
14. Fried M, Siegrist H, Frei R etal. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut [Clinical Trial Controlled Clinical Trial Research Support, Non-U.S. Gov't]. 1994;35: 23-26.
15. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit. Care Med. 2002; 30: 1118-1122.
16. Soriano G, Guarner C, Tomas A etal. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992; 103: 1267-1272.
17. Fernandez J, Ruiz del Arbol L, Gomez C etal. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131: 1049-1056; quiz 285.
18. Fernandez J, Navasa M, Planas R etal. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-824.
19. Zapater P, Cano R, Llanos L etal. Norfloxacin modulates the inflammatory response and directly affects neutrophils in patients with decompensated cirrhosis. Gastroenterology 2009; 137: 1669-1679.
20. Mazzaferro V, Regalia E, Doci R etal. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996; 334: 693-699.
21. Runyon BA. Paracentesis of ascitic fluid. A safe procedure. Arch. Intern. Med. 1986; 146: 2259-2261.
22. Such J, Frances R, Munoz C etal. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002; 36: 135-141.
23. Lane DJ. 16S/23S rRNA sequencing. In: Stackebrandt E, Goodfellow M, eds. Nucleic Acid Techniques in Bacterial Systematics. New York: John Wiley and Sons, 1991; 115-175.
24. Maidak BL, Cole JR, Lilburn TG etal. The RDP-II (Ribosomal Database Project). Nucleic Acids Res. 2001; 29: 173-174.
25. Altschul SF, Madden TL, Schaffer AA etal. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997; 25: 3389-3402.
26. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment. Pharmacol. Ther. 2011; 34: 1269-1281.
27. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955-1960.
28. Tennant SM, Hartland EL, Phumoonna T etal. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect. Immun. 2008; 76: 639-645.
29. Hopkins AM, McDonnell C, Breslin NP, O'Morain CA, Baird AW. Omeprazole increases permeability across isolated rat gastric mucosa pre-treated with an acid secretagogue. J. Pharm. Pharmacol. 2002; 54: 341-347.
30. Lichtman SM. Bacterial [correction of bacterial] translocation in humans. J. Pediatr. Gastroenterol. Nutr. 2001; 33: 1-10.
31. Basaran UN, Celayir S, Eray N, Ozturk R, Senyuz OF. The effect of an H2-receptor antagonist on small-bowel colonization and bacterial translocation in newborn rats. Pediatr. Surg. Int. 1998; 13: 118-120.
32. Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut 1992; 33: 617-621.
33. Fiuza C, Salcedo M, Clemente G, Tellado JM. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J. Infect. Dis. 2000; 182: 526-533.
34. Wenisch C, Patruta S, Daxbock F, Krause R, Horl W. Effect of age on human neutrophil function. J. Leukoc. Biol. 2000; 67: 40-45.
35. Braga PC, Sala MT, Dal Sasso M, Mancini L, Sandrini MC, Annoni G. Influence of age on oxidative bursts (chemiluminescence) of polymorphonuclear neutrophil leukocytes. Gerontology 1998; 44: 192-197.
36. Corberand J, Ngyen F, Laharrague P etal. Polymorphonuclear functions and aging in humans. J. Am. Geriatr. Soc. 1981; 29: 391-397.